Boston Scientific has raised its 2025 profit outlook to between $2.95 and $2.99 per share amid strong Q2 performance in its cardiovascular unit, driven in large part by the uptake of its Farapulse pulsed field ablation (PFA) system.
The company now anticipates an adjusted profit of $2.95 to $2.99 per share for 2025, raising its previous guidance of $2.87 to $2.94.
Boston Scientific’s financials revealed total sales of more than $5bn in Q2 2025, representing a 22.8% rise on Q2 2024 at $4.12bn, with shares in the company rising by over 4% following the result’s announcement.
The majority of the quarter’s profits emanated from the US-based company’s cardiovascular unit at $3.34bn – representing a 26.8% increase on the unit’s Q2 2024 performance at $2.63bn.
GlobalData medical analyst David Beauchamp noted that since its emergence, PFA has displaced most other approaches to treating atrial fibrillation (AFib) such as radiofrequency (RF) and cryoablation. Meanwhile, Boston Scientific only has competition in the space from Medtronic and Johnson & Johnson (J&J).
Boston Scientific gained US Food and Drug Administration (FDA) approval on Farapulse in January 2024, a month after Medtronic’s approval for its PulseSelect PFA system. J&J secured approval for its Varipulse PFA system in November 2024.
Beauchamp said: “Boston Scientific also has had widespread success with their WATCHMAN series of left atrial appendage closure devices.
“It’s not shocking to see them increasing their profit expectations, as they have been consistently successful for years and their device quality is very high.”
Elsewhere across the business, Boston Scientific reported a 26.9% rise to $676m in its urology unit, up from $525m in Q2 2024. The company’s peripheral intervention division also saw a significant increase of 18.3% to $698m versus $590m in Q2 2024.
Boston Scientific’s chairman and CEO Mike Mahoney commented: “This was another excellent quarter – marked by exceptional top-line performance – that delivered margin expansion and prioritised investment for future growth.”
Reflecting on the quarter during an earnings call with analysts, the company’s CFO John Monson said that sales for medical device makers such as Boston Scientific had been boosted due to a growth in surgical procedures, thereby helping ameliorate broader concerns about healthcare spending concerning the Trump administration’s proposed tariffs.
However, Monson commented: “Based on the current schedule of expected tariffs, we now anticipate a full-year headwind of about $100m, down from a $200m estimate.”
